257.78
前日終値:
$259.36
開ける:
$257.5
24時間の取引高:
6.15M
Relative Volume:
0.74
時価総額:
$621.22B
収益:
$97.93B
当期純損益:
$21.04B
株価収益率:
29.88
EPS:
8.6278
ネットキャッシュフロー:
$17.80B
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
-4.34%
6か月 パフォーマンス:
+13.98%
1年 パフォーマンス:
+34.34%
Johnson Johnson Stock (JNJ) Company Profile
名前
Johnson Johnson
セクター
電話
732-524-2455
住所
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Compare JNJ vs LLY, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
|
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
Johnson Johnson Stock (JNJ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-02 | 再開されました | UBS | Buy |
| 2026-05-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2026-04-08 | 再開されました | TD Cowen | Buy |
| 2026-01-28 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-10-20 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-10-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-07-23 | アップグレード | Erste Group | Hold → Buy |
| 2025-05-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-07-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-05-30 | 再開されました | Goldman | Neutral |
| 2024-04-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2023-12-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-12-01 | アップグレード | UBS | Neutral → Buy |
| 2023-10-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Hold |
| 2023-05-30 | 再開されました | Citigroup | Buy |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-14 | 繰り返されました | BofA Securities | Neutral |
| 2022-06-22 | 開始されました | Daiwa Securities | Outperform |
| 2022-05-23 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-03-16 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-15 | 繰り返されました | Citigroup | Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-05-28 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-28 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-22 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-12-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-10-16 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2019-10-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2019-07-12 | 再開されました | Credit Suisse | Outperform |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-01-23 | 繰り返されました | Barclays | Equal Weight |
| 2018-07-12 | アップグレード | Goldman | Sell → Neutral |
| 2018-06-27 | 開始されました | Bernstein | Mkt Perform |
| 2018-04-23 | 繰り返されました | Citigroup | Neutral |
| 2018-04-18 | 繰り返されました | Stifel | Hold |
| 2018-01-24 | 繰り返されました | Stifel | Hold |
| 2018-01-12 | 繰り返されました | Wells Fargo | Outperform |
| 2018-01-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2017-10-18 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-18 | 繰り返されました | Stifel | Hold |
すべてを表示
Johnson Johnson (JNJ) 最新ニュース
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now? - Zacks Investment Research
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) - The Motley Fool
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
CA-JOHNSON-&-JOHNSON - The Facts
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half - News-Press NOW
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half - Yahoo Finance
Johnson & Johnson's heart catheter halves treatment time and limits blood-flow blockage - Stock Titan
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026 - BioSpace
Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors - GlobeNewswire Inc.
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026 - Business Wire
The £4bn cancer scandal over baby powder - The Telegraph
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance
Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn’s Disease Fistula Study - Yahoo
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal - Zacks Investment Research
Has Johnson & Johnson Stock Become A Different Bet? - Yahoo Finance
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally - TipRanks
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - Yahoo Finance
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - AOL.com
Zacks Investment Ideas feature highlights: Intuitive Surgical - Zacks Investment Research
Johnson & Johnson (NYSE:JNJ): Can Drug Advances Strengthen the S&P 500? - Kalkine Media
What Does Johnson & Johnson (JNJ) News Mean For Its Growth Case? - Simply Wall Street
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law - The National Law Review
Should You Invest in This Dividend King on the Dip? - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Former J&J site cleared for £31m redevelopment - BBC
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool
Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more - Seeking Alpha
Breakfast News: Week in Review - The Motley Fool
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
3 Companies Raising Guidance This Earnings Season - Zacks Investment Research
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research
Johnson & Johnson reports mixed Q3 earnings - Healthcare Brew
Where Could Johnson & Johnson’s Next Growth Come From? - Trefis
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Johnson & Johnson CFO taps internal investment for medtech growth - CFO Dive
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView
Johnson Johnson (JNJ) 財務データ
収益
当期純利益
現金流量
EPS
Johnson Johnson (JNJ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech |
Sep 02 '26 |
Sale |
274.74 |
33,597 |
9,230,440 |
25,447 |
| Schmid Timothy | Officer |
Sep 02 '26 |
Proposed Sale |
274.74 |
33,597 |
9,230,440 |
0 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Sale |
263.36 |
15,000 |
3,950,400 |
194,451 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Option Exercise |
115.67 |
15,000 |
1,735,050 |
209,451 |
| Taubert Jennifer L | Officer |
Aug 17 '26 |
Proposed Sale |
263.36 |
15,000 |
3,950,418 |
0 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Option Exercise |
115.67 |
123,291 |
14,261,070 |
399,258 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Sale |
261.17 |
123,291 |
32,199,927 |
275,967 |
| Duato Joaquin | Officer |
Aug 13 '26 |
Proposed Sale |
261.17 |
123,291 |
32,199,927 |
0 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Option Exercise |
131.94 |
9,344 |
1,232,847 |
32,912 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Sale |
257.00 |
15,918 |
4,090,960 |
16,994 |
大文字化:
|
ボリューム (24 時間):